SpyGlass Pharma Inc.
SpyGlass Pharma Inc. (SGP): 3 pipeline candidates · 3 upcoming catalysts · ~54 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
53.9 months
D/E 0.03 · 0% dilution
Lead: Phase 3
3 candidates
3 upcoming, next in ~43d
17 buys · 0 sells (180d)
A transparent, data-derived signal for SpyGlass Pharma Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$613.8M
Cash
$238.9M
Quarterly Burn
$13.5M
Runway
53.9 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| bim-drs | Phase 3 |
| bimatoprost drug pad-iol system | Phase 3 |
| bimatoprost implant system | Phase 3 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$361.4M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 8,021,117 | $207.8M |
| samsara biocapital, llc | 2,109,953 | $54.7M |
| vanguard capital management llc | 869,626 | $22.5M |
| deerfield management company, l.p. | 550,000 | $14.3M |
| millennium management llc | 468,794 | $12.1M |
| first light asset management, llc | 375,000 | $9.7M |
| franklin resources inc | 300,000 | $7.8M |
| affinity asset advisors, llc | 250,000 | $6.5M |
| aberdeen group plc | 220,454 | $5.7M |
| blackrock, inc. | 144,739 | $3.8M |
Showing top 10 of 31 institutional holders of SpyGlass Pharma Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in SpyGlass Pharma Inc.'s pipeline?
SpyGlass Pharma Inc. (SGP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SpyGlass Pharma Inc.'s lead drug candidate?
SpyGlass Pharma Inc.'s most advanced tracked candidate is bim-drs (Phase 3) for Glaucoma.
What is SpyGlass Pharma Inc.'s next catalyst?
SpyGlass Pharma Inc.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: Prospective, Multi-Center, Open-Label, Non-Randomized, Multi-Arm Study to Evaluate the Safety, Effic" — expected July 31, 2026.
What is SpyGlass Pharma Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SpyGlass Pharma Inc. has approximately 53.9 months of cash runway.
What is SpyGlass Pharma Inc.'s market capitalization?
SpyGlass Pharma Inc.'s market capitalization is approximately $613.8M.
Get the full picture on SpyGlass Pharma Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.